#Paris #France #Eligo Bioscience #Genetic Medicine #immuno-dermatology

Eligo Bioscience Receives $5 Million to Advance Genetic Medicine

Eligo Bioscience, a pioneering biotechnology company in the field of novel genetic medicines, has made headlines today by securing a substantial grant of $5 million from the French government. This funding is aimed at accelerating the development and expansion of Eligo's proprietary topical gene delivery platform, which promises to enable local production of therapeutic biologics directly through skin-residing bacteria.

The grant comes under the initiative ‘Innovations in Biotherapies and Bioproduction’, coordinated by the French Health Innovation Agency and executed by Bpifrance, acting on behalf of the French government as part of the France 2030 strategy. This substantial financial backing follows Eligo's recent milestones, including the publication of its microbiome-based editing platform in the prestigious journal Nature and the successful expansion of its Series B funding round to $35 million. The latest non-dilutive funding further enhances Eligo’s capability to swiftly advance its clinical pipeline.

Targeting Immuno-Dermatology

Eligo Bioscience aims to revolutionize the treatment of skin conditions through its research. With a focus on chronic inflammatory and immune-mediated skin diseases, the recent funding boost will support the exploration of multiple therapeutic payloads and the establishment of a comprehensive immuno-dermatology pipeline. The skin microbiome plays a crucial role in regulating the skin immune system, and Eligo's unique in-situ delivery modality allows for genetic modifications of commensal bacteria residing in hair follicles. This approach transforms these bacteria into localized bioreactors that can express therapeutic biologics right where immune system dysregulation occurs.

Collaborating for Success

To optimize and scale the bioproduction process of its innovative gene transport vector ahead of later clinical trials, Eligo is partnering with Biose Industries, a renowned CDMO (Contract Development and Manufacturing Organization) specializing in microbial fermentation. The extensive GMP (Good Manufacturing Practices) expertise provided by Biose will be instrumental in accelerating Eligo's progress towards clinical validation. Dr. Xavier Duportet, Co-Founder and CEO of Eligo Bioscience, stated, “This funding enables us to establish a robust bioproduction process for our first topical microbiome-targeting gene editing therapies, thereby laying the groundwork for expansion into a broad range of immuno-dermatological indications.”

Conclusion

With this grant, Eligo positions itself at the forefront of biotechnological innovation in the treatment of skin diseases, aiming to meet critical medical challenges faced by millions of patients globally. The company's commitment to developing transformative therapeutic solutions underscores its aspiration for contributing significantly to healthcare advancements. For further information on Eligo Bioscience, France 2030, and Bpifrance, visit Eligo's official website.

Contact Information

For press inquiries, please reach out to: [email protected]